medRxiv preprint doi: https://doi.org/10.1101/2022.06.04.22275986; this version posted November 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Prevalence and determinants of chronic respiratory diseases in adults in Khartoum State, Sudan

Rana Ahmed[1], Nada Osman[1,2], Bandar Noory[1], Rashid Osman[1], Hana ElHassan[1], Hind Eltigani[1], Rebecca Nightingale[3], Andre FS Amaral[4], Jaymini Patel[4], Peter G. Burney[4], Kevin Mortimer[5,6] Asma ElSony[1,7]

[1]The Epidemiological Laboratory, Khartoum, Sudan

[2]Federal Ministry of Health, Sudan

[3]Liverpool School of Tropical Medicine, Liverpool, UK

[4]National Heart and Lung Institute, Imperial College, London, UK

[5]Liverpool University Hospitals NHS foundation Trust, Liverpool, UK

[6]University of Cambridge, Cambridge, UK

[7]Global Alliance for Respiratory Diseases, Africa Representative

Running head: Chronic Respiratory Disease in adults, Sudan

Word count of the summary: 198

Word count of the text: 2909

Number of references: 35

Number of tables: 3

Number of figures: 2

Correspondence and requests for reprints: Asma El Sony

Director, Head of Scientific Activities at the Epidemiological Laboratory, a WHO/EMRO Collaborating Centre for TB and Lung Diseases, PO Box 10012, Khartoum,

Phone/Fax: +24 91 5515 2445

E-mail: asmaelsony@gmail.com

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.04.22275986; this version posted November 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

SUMMARY

Background

Chronic respiratory diseases are considered a significant cause of morbidity and mortality worldwide, although data from Africa are limited. This study aimed to determine the prevalence and determinants of chronic respiratory diseases in Khartoum, Sudan.

Methods

Data was collected from 516 participants, aged ≥ 40, who had completed a questionnaire and undertook pre- and post-bronchodilator spirometry testing. Trained field workers conducted questionnaires and spirometry. Survey-weighted prevalence of respiratory symptoms and spirometric abnormalities were estimated. Regression analysis models were used to identify risk factors for chronic lung diseases.

Results

Using the NHANESIII reference equations, the prevalence of Chronic Airflow Obstruction (CAO) was 10%. The main risk factor was older age 60-69 years (Odds ratio 3.16, 95% Confidence Interval 1.20 – 8.31). Lower education, high body mass index and a history of tuberculosis were also identified as significant risk factors. The prevalence of a low forced vital capacity (FVC) using NHANES III was 62.7% [SE 2.2] and 11.3% [SE 1.4] using locally derived values.

Conclusion

The prevalence of spirometric abnormality mainly (low FVC); was high suggesting that chronic respiratory disease is of substantial public health importance in urban Sudan. Strategies for the prevention and control of these problems are needed.

Keywords: COPD, CAO, Risk factors, low FVC, SSA

medRxiv preprint doi: https://doi.org/10.1101/2022.06.04.22275986; this version posted November 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

The Global Burden of Disease Study estimates 3.9 million deaths annually from chronic non-communicable respiratory diseases – mainly chronic obstructive pulmonary disease (COPD) and asthma[1,2]. It's burden of deaths and morbidity is expected to increase over future decades especially in low-income and middle-income countries (LMICs)[3,4].

Prevalence estimates for COPD in sub-Saharan Africa (SSA)[5,6] are based on limited epidemiological data which lack a standardized definition of COPD. A recent systematic review reported a population prevalence of COPD in SSA ranging from 1.7% to 24.8%[7].

The prevalence and determinants of low FVC in SSA are barely understood however, its reported that Africans have reduced FVC compared with the Caucasian[8]. Moreover, studies reported an association between lung restriction and mortality and a higher prevalence of Chronic Respiratory Disease (CRD) in SSA that linked to numerous risk factors including early childhood exposures, poverty, biomass fuel exposure, smoking and pulmonary tuberculosis (TB) [9].

The Burden of Obstructive Lung Disease (BOLD) Initiative developed standardized methods for estimating the burden and determinants of chronic airflow obstruction (CAO) in populations aged 40 years and older[10,11]. We did a BOLD study in Khartoum, Sudan to help fill the knowledge gap about the chronic respiratory diseases in Africa.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.04.22275986; this version posted November 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

METHODS

Setting

Sudan's capital, Khartoum, is made up of 7 localities, across which there is a mix of urban, semi-urban, rural, and internally displaced populations.

Sampling

Three localities, with a total population of 661,617, were randomly selected for sampling in this study and divided into clusters. Then 280, 258 and 158 households were randomly selected from Jabelawlya, Shargalneel and Omdurman localities respectively.

Participants

Using the BOLD protocol[11], we approached 998 participants from which 600 ≥ 40 years old were included using a 3-stage stratified cluster sampling plan. Potential participants who were institutionalized or medically unfit to perform spirometry were excluded.

Data collection and management

All study participants completed a structured interview in the local Arabic language administered by trained interviewers. Anthropometric measurements along with pre-bronchodilator and post-bronchodilator spirometry data were collected following the American Thoracic Society (ATS) guidelines using the Easy One system (ndd Medizintechnik, Zurich, Switzerland) by three trained certified technicians[11]. A minimal data or refusal questionnaire was filled out for those not willing to participate in the full study. The clinical data obtained included height, weight, pulse rate and waist and hip circumference. Quality control was carried out at the BOLD coordinating centre. Usable spirometry was defined as two or more acceptable blows, with FEV_1 and FVC repeatability within 200 mL. Acceptable manoeuvres were defined as those with a rapid start (back-extrapolated volume, 150 mL or 5% of the FVC), lack of cough during the first second, and a small end-of-test volume (<40 mL during the final second). The calibration of all spirometers

medRxiv preprint doi: https://doi.org/10.1101/2022.06.04.22275986; this version posted November 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

was verified to be accurate within 3.0% using a 3.00 L syringe at the beginning of each day of testing. Spirometry traces were then classified according to FEV_1/FVC < lower limit of normality (LLN).

CAO was defined by post-bronchodilator (BD) FEV_1/FVC < LLN. Predicted values based on standardized values for age, sex, and height were calculated based on the Third National Health and Nutrition Examination Survey 1988–1994 (NHANES III) of white Americans[12]. Local values were derived from spirometry of non-smoking Sudanese adults with no respiratory symptoms or diagnoses participating in this survey. CAO stages were categorised as: stage 1 or higher CAO (Post-BD FEV_1/FVC < LLN) and stage 2 or higher CAO (Post-BD FEV_1/FVC < LLN and post-BD FEV_1 < 80% predicted).

Statistical analysis

Evaluation of selection bias and a comparison between groups was conducted using a chi-square test between participants who completed full data and minimal questionnaires with acceptable or unacceptable spirometry readings. Prevalence estimates of spirometric abnormalities stratified by age and sex were reported using the NHANES III [11]. Prevalence estimates using locally derived spirometry were also reported.

Univariable and multivariable logistic regression analyses were used to test associations between spirometry abnormalities and several exposure variables, including age, sex, education level, self-reported history of tuberculosis (TB), hypertension, diabetes, heart disease, body mass index, smoking status, smoking pack-years, exposure to indoor smoke from biomass fuel and occupational exposure.

A wealth score was developed based on the Mokken scale, to differentiate between different levels of wealth using a count of owned assets[13,14].

Multivariable logistic regression models that included sex, age and all variables from the univariable analysis with a *p*-value <0.2 were then developed. The prevalence of respiratory symptoms was reported and associations with the study variables were tested using regression analysis. A description of the associations between abnormal spirometry and respiratory

medRxiv preprint doi: https://doi.org/10.1101/2022.06.04.22275986; this version posted November 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

symptoms was reported. The data were analysed using Stata IC 14 (StataCorp, College Station, TX). Prevalence estimates and regression models were developed using survey weighting with the Svy package in Stata (14).

Ethical considerations

Written informed consent was collected from study participants before data collection. Ethical approval was obtained from the Imperial College London and Khartoum state Ministry of Health.

RESULTS

The flow of participants through the study is shown in Figure 1. Of the 998 participants approached, 516 provided full questionnaire data and had BOLD centre-approved spirometry results. Eleven of the 998 participants declined to participate fully in the study but completed the minimal data questionnaire. The final response rate was 85.5% (n=696).

Participant characteristics

These are presented in Table 1. The mean age was 53.8 years (SD 10.4) and 59.3% were men. Overall, 35% completed primary school. Men had a higher level of education, as did the group aged 40-49 years when compared to other age groups. The mean number of household members was 7.8 (SD3.56) and the mean wealth score was 5.2 (SD 2.7).

Among respondents, 24% had smoked cigarettes while 50% of men were current smokers. About 24% of smokers had more than a 20 pack-years of exposure. Exposure to indoor biomass fuel for ≥ 6 months was reported by 82% of participants. In total, 78% reported having used an indoor open fire fuelled by coal or charcoal for cooking for ≥ 6 months, while 35% used firewood and 21% used kerosene. Overall, women had a higher mean number of hours of exposure to indoor biomass fuel per year than men (70% vs. 54%). Farming was the most reported occupation (in 24%, Table 1).

medRxiv preprint doi: https://doi.org/10.1101/2022.06.04.22275986; this version posted November 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

In total, 23% of participants were obese and 7% were underweight. Hypertension was self-reported by 20% of all participants, of whom 55% were women. Diabetes was reported by 9% (9.5% of women and 8.8% of men).

Respiratory symptoms

At least one respiratory symptom was reported by 23% (Standard error (SE) 1.9) of participants; respiratory symptoms interfering with daily activities were reported by 1.9% (SE 0.5). Cough was reported by 10.4% (SE 1.3), with the highest prevalence recorded in participants aged 70+ years (11.9% [SE 4.9]). Chronic cough (lasting for more than 3 months per year) was reported by 4.0% (SE 0.8). Production of sputum was reported by 11% (SE 1.3) and chronic production of sputum (for more than 3 months per year) was reported by 5% (SE 0.09). Shortness of breath was reported by 11% (SE 1.3) and 41% (SE 6.5) of this group reported that breathing problems made it difficult to walk more than 100 yards. Wheeze in the past 12 months in the absence of cold was the least commonly reported symptom (3.0% [SE 0.7], Supplementary Table S1).

Spirometry

No statistically significant differences were found between the groups who did or did not complete the spirometry test. Using NHANES III, stage 1 or higher CAO prevalence was 10.3% [SE 1.4] (9.2 [SE 1.7] of men and 11.2 [SE 2.4] of women). Using the locally derived reference range the prevalence was 5.7% [SE 1.1] (5.2% [SE 1.3] of men and 6.2 [SE 1.9] of women).

Participants aged 60-69 years had the highest prevalence of stage 1 or higher CAO (13.4% [SE 3.8]). Prevalence of stage 2 or higher CAO was 9.4% [SE 1.4] (8.8% [SE 1.7] of men and 10.1% [SE 2.2] of women). Using the locally derived reference range, 3.0% [SE 0.8] of the study population had stage 2 or higher CAO (2.9% [SE 0.9] of men and 3.1% [SE 1.3] of women). Similarly, participants aged 60-69 years had the highest prevalence of stage 2 or higher CAO using both the local and NHANES reference ranges (17.6% [SE 4.2] vs. 6.7% [SE 2.6]).

medRxiv preprint doi: https://doi.org/10.1101/2022.06.04.22275986; this version posted November 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Low FVC was seen in 62.7% [SE 2.2] (65.2% [SE 2.8] in men vs. 59.8% [SE 3.5] in women). Cough was less reported in those with low FVC (OR 0.48, 95% CI 0.27 - 0.87).

Airflow reversibility was found in 6.1% [SE 1.1] of the total study population and was more common in women than men (8% [SE 1.9] vs. 4.4% [SE 1.1]). Airflow obstruction persisted after use of a bronchodilator in 8.4% (SE 4.7) of participants with reversibility. (Supplementary Table S2, Figure 2).

Factors associated with respiratory symptoms

In both univariable and multivariable analyses, chronic production of sputum was negatively associated with age (Supplementary Tables S3 and S4). Participants aged 60-69 years were less likely to report chronic sputum production (OR 0.39, 95% CI 0.16 - 0.93) than those aged 40-49 years. There was a significantly increased likelihood of regular sputum production with being an ex-smoker (OR 2.66, 95% CI 1.09 - 6.50) and having diabetes (OR 4.04, 95% CI 1.82 - 8.96). Participants with lower socioeconomic status; who have a wealth score of 2 tend to have higher odds of sputum production compared to those with zero score (OR 7.18, 95% CI 1.16 - 44.53).

In multivariable analysis, the likelihood of having shortness of breath was significantly greater in participants exposed to indoor biomass fuel (OR 4.56, 95% CI 1.44 - 14.43). The presence of wheeze was only associated with being a current smoker (OR 3.49, 95% CI 1.02 - 11.96). There were no significant associations between CAO and respiratory symptoms.

Factors associated with post-bronchodilator airway obstruction

Participants aged 60-69 years had the highest risks of CAO stage 1 or higher (OR 3.16, 95% CI 1.20 - 8.31) and stage 2 or higher (OR 3.39, 95% CI 1.04 - 6.93) than those aged 40-49 years. In contrast, having higher education level was protective against any obstruction in bivariate analysis (OR 0.31, 95% CI 0.13 - 0.76), however no association was identified after adjustment. Similarly, being overweight or obese was protective against any obstruction (OR 0.38,

medRxiv preprint doi: https://doi.org/10.1101/2022.06.04.22275986; this version posted November 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

95% CI 0.17 - 0.82 and OR 0.34, 95% CI 0.13 - 0.99, respectively). Those with a history of TB were less likely to have any obstruction (OR 0.08, 95% CI 0.01 - 0.59). There was no observed trend in Mokken scale points and CAO. However, participants with a low socioeconomic position who scored ≥2 in wealth score had the highest odds of developing stage 1 or higher and stage 2 or higher CAO (OR 6.00, 95% CI 1.03 - 34.94). No other factor was significantly associated with airway obstruction (Table 2, Supplementary Tables S5 and S6).

Using the local reference range, participants aged 60-69 years were more likely to have CAO stage 1 or higher than their younger counterparts (OR 3.10, 95% CI 1.01 - 9.57), and being obese were negatively associated with obstruction (OR 0.29, 95% CI 0.09 - 0.97) in multivariable analysis. A higher education level was protective against CAO in the bivariate analysis (OR 0.23, 95% CI 0.063 - 0.83) however no association was identified after adjustment.

Factors associated with low FVC

Using the NHANES III, low FVC was associated with smoking 10-20 packs year history, having primary or higher-level education, having more people in house and being obese (OR 2.79, 95% CI 1.11 - 7.00; OR 2.42, 95% CI 1.43 - 4.09; OR 0.94, 95% CI 0.89 - 0.99 and OR 1.73, 95% CI 1.04 - 2.86 respectively) in bivariate analysis. In multivariate analysis, those aged 50-59 were less likely to have low FVC compared to those aged 40-49 years (OR 0.50, 95%CI 0.31 - 0.81). No other factors were associated with low FVC in multivariate analysis (Table 3).

DISCUSSION

This population-based survey aimed to investigate the prevalence and determinants of chronic respiratory diseases in the population aged ≥40 years in urban Sudan. Our main finding was that approximately 10% of people in this age group had CAO. CAO stage II or higher was detected in 9.4% of the overall population using the same reference range, though this decreased to 3.0% when the local reference range was used.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.04.22275986; this version posted November 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

A higher prevalence of obstruction when using the NHANES III compared to the local reference range has been reported previously[9]. In spite of being the only available data, values of the local methodology might be more ethnically suitable compared to NHANES III. However, different exposures in this setting may constrain its use[9,15].

The determined prevalence of spirometric obstruction is consistent with that in similar studies from sub-Saharan Africa, where the prevalence of smoking is high[16]. Previous BOLD studies reported COPD prevalence of 23% in men and 16.9% in women in South Africa[17] and 7.7% in Nigeria[7,18,19]. CAO prevalence reported from a multinational BOLD study was 11.5% in men and 8.8% in women which is consistent with our findings[20]. Compared to studies from the MENA region (Middle East and North Africa), our findings are higher than those in Saudi Arabia[21], Tunisia[22,23], Morocco[24], Algeria[25] and Lebanon[26].

Older age was the main risk factor for CAO in our study, which is consistent with both regional and global findings[7,9,16,18]. The absence of an association with CAO and cigarette smoking might be due to that 50% of the smokers in our study reported a smoking history of ≤10 pack-years. Countries with lower smoking rates, such as Malawi and Rwanda, have a lower reported prevalence of COPD[9,27]. However, the age group 60-69 years who reported the highest smoking rates in this study had the highest prevalence of spirometric obstruction and higher prevalence of both chronic cough and chronic phlegm. The high prevalence of CAO might be due to exposure to air pollutants coming from the large number of factories and cars in the State.

A higher educational level was protective against CAO which is compatible with other studies[10,18,28]. Conversely, a significant association between low socioeconomic status and developing CAO was found in this study, consistent with studies suggesting that low socioeconomic status may be associated with a progression of airflow limitation[16,29].

We did not observe any association between exposure to biomass fuel and obstruction. This is consistent with the study that included 25 BOLD sites which found that airflow obstruction measured by post-bronchodilator spirometry was not associated with use of solid fuels for cooking or heating[30],

medRxiv preprint doi: https://doi.org/10.1101/2022.06.04.22275986; this version posted November 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

and findings in other large studies in China[31,32]. A recent review of studies on COPD and household air pollution concluded that it was not possible to define clear causal links between the two[33].

Shortness of breath, one of the most common symptoms of CAO, was significantly higher in those who use biomass fuel for ≥ 6 months. It is possible that this latter group suffer from chronic bronchitis or similar non-obstructive lung diseases. In addition, the finding that only 0.2% reported TB might account for the significant negative association between TB and obstruction, which is in conflict with published literature[34]. Identification of TB was based on self-reporting and many factors might affect the validity of the answers provided given that TB is a highly stigmatized clinical condition and the proportion reported here may be an underestimate[35].

A high prevalence of low FVC (62.7%) was identified in this study. BOLD studies in SSA and other studies in resource-poor settings reports similar findings [9,17]. That 55% of the study population was overweight might partly explain the high level of low FVC[8].

To our knowledge, this is the first study to provide a detailed prevalence estimates of CAO in Sudanese adults using internationally standardised methods and procedures as well as an appropriate sampling technique. We acknowledge our study had limitations. Missing information for a proportion of the study participants limited the cluster-weighted analysis. Furthermore, reasons for exclusion were not recorded, meaning those who were excluded for medical reasons were not separated from those who were excluded for other reasons. Having spirometry readings with no matching questionnaire data for 54 participants and unacceptable spirometry readings from 79 participants decreased the sample size and study power.

In conclusion, this study found evidence that chronic respiratory disease is a major problem in Sudan and needs to be considered in future public health policies and research. The overall prevalence of CAO in urban Sudan is similar to that found by other BOLD studies in countries with similar smoking rates. However, it is relatively high when compared to other countries in sub-Saharan Africa and the MENA regions. A high prevalence of low FVC was

medRxiv preprint doi: https://doi.org/10.1101/2022.06.04.22275986; this version posted November 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

also identified, the aetiology and pathophysiology of which are unknown and require further investigation. These findings suggest the need for strengthening the chronic respiratory disease programs and provision of improved diagnostic and treatment options for CRDs to address underestimation and diagnosis.

ACKNOWLEDGEMENTS

This work was supported by Welcome Trust, UK - grant (085790/Z/08/Z) for the

BOLD (Burden of Obstructive Lung Disease) study. Prof. Mortimer received advisory board fees from AstraZeneca outside this work and Dr Nightingale reports grants from Medical Research Council, outside the submitted work.

We thank the teams of data collectors and spirometry technicians from Sudan for their hard work during the household survey. We also thank the members of the BOLD Coordinating Centre at the Imperial College London for its assistance with spirometry training, quality control, and data management in the study.

CONTRIBUTION STATEMENT

Dr Rana Ahmed wrote the first draft of manuscript, conducted data cleaning, verification, interpretation and analysis of this study.

Dr Nada Osman lead the study and contributed to manuscript writing and revision.

Dr Bandar Noory coordinated the study, supervised the data collection and contributed to manuscript writing and revision.

Dr Rashid Osman revised the spirometry readings, contributed to the writing and revision.

Ms Hind Eltigani contributed to data collection, data verification and participated in writing.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.04.22275986; this version posted November 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Ms Hana ElHassan was responsible for the field administration of the overall project. She contributed to the writing and revision.

Dr Rebecca Nightingale contributed to the writing and analysis of this manuscript.

Dr Andre FS Amaral reviewed and contributed to the writing of this manuscript.

Mrs. Jaymini Patel provided the clean data, analysis report and revised the manuscript.

Prof. Burney reviewed and contributed to the methodology of the study and reviewed the writing of this manuscript.

Prof. Kevin Mortimer supervised, reviewed and contributed to the writing of this manuscript.

Prof. Asma El Sony was the principal investigator of the study, she supervised, reviewed and contributed to the writing of this manuscript.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.04.22275986; this version posted November 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

REFERENCES

1. Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020;396(10258):1204-1222. doi:10.1016/S0140-6736(20)30925-9

2. Global Burden of Disease Collaborative Network.Global Burden of Disease Study 2019 (GBD 2019) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2020. Global Health Data Exchange. http://ghdx.healthdata.org/gbd-results-tool. Published 2019.

3. de-Graft Aikins A, Unwin N, Agyemang C, Allotey P, Campbell C, Arhinful D. Tackling Africa's chronic disease burden: from the local to the global. *Global Health*. 2010;6(August 2016):5. doi:10.1186/1744-8603-6-5

4. Meghji J, Mortimer K, Agusti A, et al. Improving lung health in low-income and middle-income countries: from challenges to solutions. *Lancet*. 2021;397(10277):928-940. doi:10.1016/S0140-6736(21)00458-X

5. Salvi S. The silent epidemic of COPD in Africa. *Lancet Glob Heal*. 2015;3(1):e6-e7. doi:10.1016/S2214-109X(14)70359-6

6. Mannino DM. COPD in Africa: the coming storm. *Int J Tuberc Lung Dis*. 2013;17(5):572. doi:10.5588/ijtld.13.0157

7. Awokola BI, Amusa GA, Jewell CP, et al. Chronic obstructive pulmonary disease in sub-Saharan Africa. *Int J Tuberc Lung Dis*. 2022;26(3):232-242. doi:10.5588/ijtld.21.0394

8. Obaseki DO, Erhabor GE, Awopeju OF, et al. Reduced forced vital capacity in an African population prevalence and risk factors. *Ann Am Thorac Soc*. 2017;14(5):714-721. doi:10.1513/AnnalsATS.201608-598OC

medRxiv preprint doi: https://doi.org/10.1101/2022.06.04.22275986; this version posted November 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

9. Meghji J, Nadeau G, Davis KJ, et al. Noncommunicable lung disease in sub-Saharan Africa a community-based cross-sectional study of adults in urban Malawi. *Am J Respir Crit Care Med*. 2016;194(1). doi:10.1164/rccm.201509-1807OC

10. Buist a. S, Vollmer WM, McBurnie M a. Worldwide burden of COPD in high- and low-income countries. Part I. The burden of obstructive lung disease (BOLD) initiative. *Int J Tuberc Lung Dis*. 2008;12(7):703-708. doi:S0140-6736(07)61377-4 [pii] 10.1016/S0140-6736(07)61377-4 [doi]

11. Buist AS, Vollmer WM, Sullivan SD, et al. The Burden of Obstructive Lung Disease Initiative (BOLD): rationale and design. *COPD*. 2005;2(2):277-283. doi:10.1081/COPD-200057610

12. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. Population. *Am J Respir Crit Care Med*. 1999;159(1):179-187. doi:10.1164/ajrccm.159.1.9712108

13. Townend J, Minelli C, Harrabi I, et al. Development of an international scale of socio-economic position based on household assets. *Emerg Themes Epidemiol*. 2015;12(1):1-11. doi:10.1186/s12982-015-0035-6

14. Townend J, Minelli C, Mortimer K, et al. The association between chronic airflow obstruction and poverty in 12 sites of the multinational BOLD study. *Eur Respir J*. 2017;49(6).

15. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: The global lung function 2012 equations. *Eur Respir J*. 2012;40(6):1324-1343. doi:10.1183/09031936.00080312

16. Adeloye D, Basquill C, Papana A, Chan KY, Rudan I, Campbell H. An Estimate of the Prevalence of COPD in Africa: A Systematic Analysis. *COPD J Chronic Obstr Pulm Dis*. 2015;12(1):71-81. doi:10.3109/15412555.2014.908834

17. Burney P, Jithoo A, Kato B, et al. Chronic obstructive pulmonary disease mortality and prevalence: the associations with smoking and poverty—a BOLD analysis. *Thorax*. 2014;69(5):465-473.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.04.22275986; this version posted November 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

doi:10.1136/thoraxjnl-2013-204460

18. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. *Lancet*. 2007;370(9589):741-750. doi:10.1016/S0140-6736(07)61377-4

19. Obaseki DO, Erhabor GE, Gnatiuc L, Adewole OO, Buist SA, Burney PG. Chronic Airflow Obstruction in a Black African Population: Results of BOLD Study, Ile-Ife, Nigeria. *COPD J Chronic Obstr Pulm Dis*. 2016;13(1):42-49. doi:10.3109/15412555.2015.1041102

20. Burney P, Patel J, Minelli C, et al. Prevalence and Population Attributable Risk for Chronic Airflow Obstruction in a Large Multinational Study. *Am J Respir Crit Care Med*. November 2020. doi:10.1164/rccm.202005-1990OC

21. Al Ghobain M, Alhamad EH, Alorainy HS, Al Kassimi F, Lababidi H, Al-Hajjaj MS. The prevalence of chronic obstructive pulmonary disease in Riyadh, Saudi Arabia: a BOLD study. *Int J Tuberc Lung Dis*. 2015;19(10):1252-1257. doi:10.5588/ijtld.14.0939

22. Daldoul H, Denguezli M, Jithoo A, et al. Prevalence of COPD and tobacco smoking in Tunisia - Results from the BOLD study. *Int J Environ Res Public Health*. 2013;10(12):7257-7271. doi:10.3390/ijerph10127257

23. Denguezli M, Daldoul H, Harrabi I, et al. COPD in Nonsmokers: Reports from the Tunisian Population-Based Burden of Obstructive Lung Disease Study. *PLoS One*. 2016;11(3):e0151981. doi:10.1371/journal.pone.0151981

24. El Rhazi K, Nejjari C, BenJelloun MC, El Biaze M, Attassi M, Garcia-Larsen V. Prevalence of chronic obstructive pulmonary disease in Fez, Morocco: results from the BOLD study. *Int J Tuberc Lung Dis*. 2016;20(1):136-141. doi:10.5588/ijtld.15.0029

25. Hacene Cherkaski H, Khalloufi F, Atoui F, et al. The prevalence of COPD in Annaba, Algeria: Results of the BOLD study. *Eur Respir J*.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.04.22275986; this version posted November 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

2014;44(Suppl 58).

26. Ben Abdallah FC, Taktak S, Chtourou A, Mahouachi R, Kheder A Ben. Burden of Chronic Respiratory Diseases (CRD) in Middle East and North Africa (MENA). *World Allergy Organ J*. 2011;4(1 Suppl):S6-8. doi:10.1097/WOX.0b013e3182093cbb

27. Musafiri S, Joos G, Van Meerbeeck JP. Asthma, atopy and COPD in sub-Saharan countries: the challenges. *East Afr J Public Health*. 2011;8(2):161-163.

28. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. *Lancet*. 2007;370(9589):765-773. doi:10.1016/S0140-6736(07)61380-4

29. Lamprecht B, McBurnie MA, Vollmer WM, et al. COPD in never smokers: Results from the population-based burden of obstructive lung disease study. *Chest*. 2011;139(4):752-763. doi:10.1378/chest.10-1253

30. André FSA, Jaymini P, Bernet SK, Al E. Airflow obstruction and use of solid fuels for cooking or heating: BOLD results. *Am J Respir Crit Care Med*. 2017;182(6):745-751. doi:10.1164/rccm.201003-0326OC

31. Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. *Lancet*. 2018;391(10131):1706-1717. doi:https://doi.org/10.1016/S0140-6736(18)30841-9

32. Fang L, Gao P, Bao H, et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study. *Lancet Respir Med*. 2018;6(6):421-430. doi:https://doi.org/10.1016/S2213-2600(18)30103-6

33. Mortimer K, de Oca MM, Salvi S, et al. Household air pollution and COPD: cause and effect or confounding by other aspects of poverty? *Int J Tuberc Lung Dis*. 2022;26(3):206. doi:10.5588/ijtld.21.0570

34. Osman RK, Mortimer K, Bjune G, Sony AI El. Chronic respiratory disease in adults treated for tuberculosis in Khartoum, Sudan. *Public Heal Action*. 2016;I(3):199-204.

medRxiv preprint doi: https://doi.org/10.1101/2022.06.04.22275986; this version posted November 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

35. Ziyada MM. Exploring tuberculosis Related Stigma in Khartoum-Sudan□: A qualitative study. 2010;(September). doi:10.13140/RG.2.1.4193.8804

Table 1 Characteristics of all subjects who completed a full BOLD core questionnaire, including those with and without spirometry results

Variable (n)	n (%)
Age group, years (n=595)	
40–49	226 (38.0)
50–59	200 (33.6)
60–69	108 (18.2)
70+	61 (10.3)
Sex (n=595)	
Male	353 (59.3)
Female	242 (40.7)
Level of education (n=593)	
None	125 (21.1)
Primary school	207 (34.9)
Middle school	69 (11.6)
High school or above	192 (32.4)
Mean years of education (n=595)	6.49 (5.5)
Smoking status (n=595)	
Current smoker	55 (9.2)
Ex-smoker	86 (14.5)
Never smoked	454 (76.3)
Pack-years of smoking (n=595)	
Never smoked	454 (76.3)
0 -10	71 (11.9)
10-20	36(6.1)
≥20	34(5.7)
Biomass exposure (n=532)	
Yes	422 (82.4)
No	90 (17.6)
Farm work for ≥3 months (n=527)	
Yes	126 (23.9)
No	401 (76.1)
Body mass index (n=588)	
Underweight (<18.5)	39 (6.6)
Normal (18.5–24.9)	226 (38.4)
Overweight (25.0–29.9)	189 (32.1)
Obese (≥30)	134 (22.8)
Reported history of tuberculosis (n=595)	
Yes	5 (0.8)

medRxiv preprint doi: https://doi.org/10.1101/2022.06.04.22275986; this version posted November 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

No	590 (99.2)
Reported history of hypertension (n=595)	
Yes	118 (19.8)
No	477 (80.2)
Reported history of diabetes (n=595)	
Yes	54 (9.1)
No	541 (90.9)
Reported history of heart disease (n=595)	
Yes	12 (2.0)
No	583 (98.0)

Table 2 Multivariable associations of risk factors with stage 1 or higher CAO defined using NHANES III (Post-BD FEV_1/FVC < LLN; n=53/516) and Stage 2 or higher CAO defined using NHANES III (Post-BD FEV1/FVC < LLN and post-BD FEV_1 < 80% predicted; n=49/516)

Variable	Multivariable association with CAO stage 1 or higher		Multivariable association with CAO stage 2 or higher	
	OR	95% CI	OR	95% CI
Age group, years				
40–49	1.0	-	1.0	-
50–59	2.13	0.84 - 5.41	1.86	0.73 - 4.77
60–69	3.16 *	1.20 - 8.32	2.78*	1.07 - 7.26
70+	1.91	0.60 - 6.10	0.91	0.21 - 3.92
Sex				
Male	1.0	-	1.0	-
Female	1.31	0.61 - 2.84	1.67	0.76 - 3.66
Level of education				
None	1.0	-	1.0	-
Primary school	0.61	0.27 - 1.34	0.62	0.27 - 1.44
Middle school	1.23	0.40 - 3.81	1.03	0.32 - 3.36
High school or above	0.71	0.28 - 1.78	0.69	0.26 - 1.86
Body mass index				
Underweight (<18.5)	1.87	0.66 - 5.30	1.16	0.33 - 4.07
Normal (18.5–24.9)	1.0	-	-	
Overweight (25.0–29.9)	0.43	0.18 - 1.01	0.37*	0.15 - 0.92
Obese (≥30)	0.35	0.11 - 1.17	0.29*	0.08 - 1.07
Self-reported TB				
No	1.0	-	1.0	0
Yes	0.08*	0.01 - 0.59	0.07*	0.01 - 0.48
Number of people living in	±	±	1.05	0.96 - 1.16
Used firewood				
No	±	±	1.0	-
Yes	±	±	0.58	0.29 - 1.19
Wealth score/Mokken scale	±	±	0.96	0.83 - 1.11

medRxiv preprint doi: https://doi.org/10.1101/2022.06.04.22275986; this version posted November 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

*p <0.05. CAO, Chronic Airflow Obstruction; CI, confidence interval; OR, odds ratio; FEV_1, forced expiratory volume in 1 second; FVC, forced vital capacity ratio; LLN, lower limit of normal, (±) not included in multivariable analysis

Table 3 Multivariable associations of risk factors with low FVC, defined using NHANES III reference range (FVC < LLN), n= 315/516

Variable	Multivariable association	
	OR	95% CI
Age group		
40-49	1	-
50-59	0.50*	0.31 - 0.81
60-69	0.29*	0.17 - 0.51
70+	0.25*	0.12 - 0.53
Sex		
Male	1	-
Female	0.78	0.48 - 1.24
Body Mass Index (kg/m2)		
Underweight (BMI<18.5)	0.95	0.43 - 2.07
Normal (BMI 18-25)	1	-
Overweight (BMI 25-30)	1.39	0.85 - 2.27
Obese (BMI >30)	1.55	0.87 - 2.80
Packs-year of smoking		
Never	1	-
0-10	1.09	0.59 - 2.02
10-20	2.45	0.88 - 6.86
≥20	1.00	0.47 - 2.11
Wealth score/Mokken scale	0.97	0.90 -1.04

*p <0.05. CI, confidence interval; OR, odds ratio; FVC, forced vital capacity ratio; LLN, lower limit of normal

medRxiv preprint doi: https://doi.org/10.1101/2022.06.04.22275986; this version posted November 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Figure 1 Participant flow diagram

Figure 2 Estimated Population Prevalence of chronic airflow obstruction by age and sex using National Health and Nutrition Examination Survey reference ranges (NHANES) for the Sudanese population in participants completing standard American Thoracic Society spirometry (n=516). The upper graph represents the prevalence of Stage 1 or higher CAO (Post-BD FEV1/FVC < LLN) and the lower graph represents the prevalence of Stage 2 or higher CAO (Post-BD FEV1/FVC < LLN and post-BD FEV1 < 80% predicted).